Trials / Unknown
UnknownNCT05374343
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment
A Phase I Study of the Pharmacokinetics/Pharmacodynamics and Safety of Rongliflozin in Chinese Subjects With Type 2 Diabetes With Normal Renal Function and Mild to Moderate Renal Impairment
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the pharmacokinetic characteristics of pyroglutamate rongliflozin capsules in type 2 diabetic subjects with normal renal function and mild to moderate renal impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pyroglutamate rongliflozin capsules | Subjects will receive one 50mg capsule orally (by mouth) on Day 1 |
Timeline
- Start date
- 2022-05-05
- Primary completion
- 2023-11-15
- Completion
- 2024-02-13
- First posted
- 2022-05-16
- Last updated
- 2022-05-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05374343. Inclusion in this directory is not an endorsement.